TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06100289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab SC
Description: Vedolizumab SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab SC
Description: Vedolizumab SC injection.
Study: NCT05282927

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implementation Strategy: Foundational REP
Description: The goal is to test implementation intensification approaches for group PT sites that have not met implementation adoption benchmarks, specifically Foundational REP vs. Enhanced REP. The investigators propose that low intensity implementation support that promotes adapting Group PT for context and provides tools for ongoing evaluation (defined as foundational REP), will be sufficient for some but not all sites to successfully implement group PT as a clinical service.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation Strategy: Enhanced REP (enREP)
Description: The goal is to test implementation intensification approaches for sites that have not met implementation adoption benchmarks, specifically Foundational REP vs. EnREP. The investigators posit that monitoring sites' progress and adding, for sites with low adoption, higher intensity strategies (defined as EnREP) that directly influence teams' capacity and skills to effectively self-organize and problem-solve will lead to higher implementation adoption, penetration, fidelity, and value.
Study: NCT06158724

Intervention type: OTHER
Intervention: Personal Protective Equipment
Description: Simplified PPE for use in COVID-19 departments.
Study: NCT04221438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluorothymidine F-18
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT04438213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metolazone
Description: Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
Study: NCT05371093

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously
Study: NCT05371093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously
Study: NCT05907590

Intervention type: OTHER
Intervention: Proprioceptive accuracy measurement of the neck
Description: The head reposition accuracy task will be carried out to assess proprioceptive accuracy of the neck. The most commonly used procedure is the head repositioning accuracy to neutral head position (HRA-to-NHP), first described by Revel and colleagues (1991).

Intervention type: OTHER
Intervention: Proprioceptive accuracy measurement of the neck
Description: The head reposition accuracy task will be carried out to assess proprioceptive accuracy of the neck. The most commonly used procedure is the head repositioning accuracy to neutral head position (HRA-to-NHP), first described by Revel and colleagues (1991).
Study: NCT05031273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Residents moving into a congregate-living development with more features that support healthy living
Description: Our team is making evidence-based recommendations to the developer and design team of an upcoming congregate-living development to support the physical activity, healthy eating, and social connections of residents moving into the new building(s). We hope for the developer to integrate into the new building(s) as many as possible of our team's built environment design and amenity recommendations into their site and/or building plans. Additionally, discussions with the municipality are also occuring on built environment design and amenity recommendations to improve the neighbourhood surrounding the site. Although our team has provided these recommendations, it is ulimatily up to the discretion of the developer and the municipality as to whether and what design and amenity changes are made.
Study: NCT04686604

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best practice alert for the notification of patient HFrEF and recommended evidence-based medical therapies (NO drugs are being administered in this trial)
Description: Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction, most recent blood pressure and heart rate, most recent potassium and estimated glomerular filtration rate, and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
Study: NCT04898387

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bimatoprost Timolol (T4030)
Description: Eye drop

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost Timolol (Ganfort)
Description: Eye drop
Study: NCT05400824

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood, DNA, feces, urine, hair and skin microbiota collection
Description: See above
Study: NCT04967456

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Measurement of pulpal blood flow of traumatised tooth
Description: Measurement of the blood flow of the dental pulp will be performed, using a laser doppler flow monitor mVMS-LDF2TM (Moor Instruments Ltd Millwey Axminster Devon, UK), emission wavelength 785nm±10nm, dual-channel laser Doppler monitoring option. Two probes will be used, each consisting of one afferent and one efferent optic fiber to conduct the light to and from the tooth surface. The probe is stainless steel needle-like tube, which is 10-80 mm long and 1.5 mm in the diameter. The utilised parameter settings will be: Average power - 1.0 mV; Diameter of the probe - 1.5 mm; Frequency - 40 Hz; Monitoring time-180 seconds (sec)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of pulpal blood flow of traumatised tooth
Description: Measurement of the blood flow of the dental pulp will be performed, using a laser doppler flow monitor mVMS-LDF2TM (Moor Instruments Ltd Millwey Axminster Devon, UK), emission wavelength 785nm±10nm, dual-channel laser Doppler monitoring option. Two probes will be used, each consisting of one afferent and one efferent optic fiber to conduct the light to and from the tooth surface. The probe is stainless steel needle-like tube, which is 10-80 mm long and 1.5 mm in the diameter. The utilised parameter settings will be: Average power - 1.0 mV; Diameter of the probe - 1.5 mm; Frequency - 40 Hz; Monitoring time-180 seconds (sec)
Study: NCT04647760

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: JOIN for ME
Description: JOIN for ME is an empirically tested, effective weight management program for children ages 6-12 years.The curriculum includes 16 weekly in person sessions followed by 4 biweekly and 4 monthly maintenance sessions for a 10-month program. Weekly meetings are attended by the parent/caregiver and child, and occur at a location within their community setting (public housing or patient-centered medical home). Each session is 60 minutes and led by a certified Community Health Worker, with a private weigh-in for each dyad prior to the start of each session. Key behavioral targets include self-monitoring of dietary intake and physical activity, limiting LESS foods, limiting screen time, and weekly attendance. A family-based incentive structure is incorporated into the program such that parents/caregivers reinforce their children for achieving goals. Due to the COVID-19 pandemic, in-person sessions will be conducted virtually until it is safe to resume in-person group sessions.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: JOIN for ME
Description: JOIN for ME is an empirically tested, effective weight management program for children ages 6-12 years.The curriculum includes 16 weekly in person sessions followed by 4 biweekly and 4 monthly maintenance sessions for a 10-month program. Weekly meetings are attended by the parent/caregiver and child, and occur at a location within their community setting (public housing or patient-centered medical home). Each session is 60 minutes and led by a certified Community Health Worker, with a private weigh-in for each dyad prior to the start of each session. Key behavioral targets include self-monitoring of dietary intake and physical activity, limiting LESS foods, limiting screen time, and weekly attendance. A family-based incentive structure is incorporated into the program such that parents/caregivers reinforce their children for achieving goals. Due to the COVID-19 pandemic, in-person sessions will be conducted virtually until it is safe to resume in-person group sessions.
Study: NCT05371093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Administered intravenously
Study: NCT06111027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibro-tactile stimulation
Description: Vibro-tactile stimulation is a non-invasive treatment option. As stimulators, we will apply a pair of light-weight encapsulated cylindrical vibrators to both sides of the larynx (voice box). The vibration frequency for VTS will set be to 100Hz and the participant may feel a mild tingling or vibrating sensation during VTS. The participants will be asked to apply for VTS at home over a period of 8 weeks. The participants will be asked to use this device for 3 days in the first week, 4 days in the second week, 5 days in the third week and 6 days in the fourth week. During the last 4 weeks, the participants will apply VTS on self-selected days as needed, not exceeding 6 times a week, to control and improve symptoms.
Study: NCT06267911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation and psychological support (RGS-ICU)
Description: The RGS-ICU intervention consists of daily 20-minute sessions of early cognitive stimulation and psychological support adjuvant to standard ICU care administered by research staff and supervised by clinical staff each morning in the patient's own room during ICU admission and until ICU discharge or up to a maximum of 28 days after randomization. The sessions consist of orienting the patient to space and time, cognitive training of attention, working memory, learning/memory, executive function and processing speed, viewing of relaxing videos inspired by nature and fantasy scenarios to reduce stress and anxiety, and psychoeducation about the ICU environment and the characteristics of the cognitive, mental and physical state of critically ill patients.
Study: NCT06115954

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Management Supported Telerehabilitation
Description: Supporting the exercises with an internet-based environment and self-management training for Children and Adolescents with Juvenile Idiopathic Arthritis
Study: NCT05715541

Intervention type: OTHER
Group type: OTHER
Intervention: mobile applications with the name Set My INR
Description: The relevant software company assisted in developing the phone application. The language of the application created with the name Set My INR is Turkish. The application provided an opportunity for patients to share and communicate with their physician after having the INR value measured in a health institution near their place of residence before coming to the hospital
Study: NCT06115954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Management Supported Telerehabilitation
Description: Supporting the exercises with an internet-based environment and self-management training for Children and Adolescents with Juvenile Idiopathic Arthritis
Study: NCT06057220

Intervention type: OTHER
Intervention: No intervention sample collection only
Description: No intervention

Intervention type: OTHER
Intervention: No intervention sample collection only
Description: No intervention

Intervention type: OTHER
Intervention: No intervention sample collection only
Description: No intervention

Intervention type: OTHER
Intervention: No intervention sample collection only
Description: No intervention
Study: NCT05227313

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eefooton oral solution
Description: Eefooton is extracted from Rhodiola, Huang Qi, American Ginseng, Dang Ginseng, and Ligustrum lucidum by biotechnology. It has immunomodulatory effects, anti-oxidation and anti-inflammatory effects, and regulates calcium metabolism.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Eefooton oral solution
Description: Eefooton is extracted from Rhodiola, Huang Qi, American Ginseng, Dang Ginseng, and Ligustrum lucidum by biotechnology. It has immunomodulatory effects, anti-oxidation and anti-inflammatory effects, and regulates calcium metabolism.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo oral solution
Description: oral solution matched placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral solution
Description: oral solution matched placebo
Study: NCT04935593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The RENEW Intervention
Description: An game-based intervention that will provide lessons and activities in social-awareness, self-management, self-awareness, relationships and decision making in effort to strengthen social, emotional and behavioral competence. The intervention will be administered tri-weekly for 20 minutes each session.
Study: NCT05756426

Intervention type: OTHER
Intervention: Prospective
Description: Single arm, healthy adult volunteers for blood donation.
Study: NCT05794373

Intervention type: PROCEDURE
Intervention: Standard physiotherapy for low back pain in a municipality setting
Description: Patients (N=100) referred to a municipality-based rehabilitation for low back pain are included. The physiotherapists choose the rehabilitation strategy based on what they consider relevant for the patients. After the first 100 patients have been discharged from municipality care, the physiotherapists will participate in an educational intervention (12 sessions) focusing on the management of low back pain within a multidimensional framework. In the educational intervention, the participants will learn how to identify the presence of unhelpful thoughts and emotions and how to address these as part of the intervention. The course will thus be a mix of theoretical and practical teaching, including case supervision and feedback. Following the educational intervention, an additional 100 patients referred to the rehabilitation program will be included. The intervention is aimed at the physiotherapists where the patients will receive the best available care, before or after the intervention.

Intervention type: PROCEDURE
Intervention: Standard physiotherapy for low back pain in a municipality setting
Description: Patients (N=100) referred to a municipality-based rehabilitation for low back pain are included. The physiotherapists choose the rehabilitation strategy based on what they consider relevant for the patients. After the first 100 patients have been discharged from municipality care, the physiotherapists will participate in an educational intervention (12 sessions) focusing on the management of low back pain within a multidimensional framework. In the educational intervention, the participants will learn how to identify the presence of unhelpful thoughts and emotions and how to address these as part of the intervention. The course will thus be a mix of theoretical and practical teaching, including case supervision and feedback. Following the educational intervention, an additional 100 patients referred to the rehabilitation program will be included. The intervention is aimed at the physiotherapists where the patients will receive the best available care, before or after the intervention.
Study: NCT05360277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab + Capecitabine
Description: Tislelizumab 200mg iv every 3 weeks, for 1 year after completion of perioperative chemotherapy.~Capecitabine was given at a dose of 850 mg/m2 twice a day by mouth, 2 weeks on/ 1 week off, for 1 year after completion of perioperative chemotherapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best supportive care
Description: Best supportive care
Study: NCT05556239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training
Description: Supervised resistance training program planned as 3 sessions per week of approximately 60 minutes. The resistance training program comprises 6 exercises for the major muscle groups, starting at 2 sets of 15 repetitions maximum progressing to 4 sets of 8 repetitions maximum. Each session will be supervised by physiotherapist to ensure proper technique, and progression in training load. The participants will choose an exercise ambassador from their network, who during the period will be encouraged to, on a weekly basis, to be in contact with the participant.
Study: NCT06200948

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: While the patients in non-cycling group will get only complete decongestive treatment (CDT) for 3 weeks, the patients in cycling group will get CDT+cycling ergometry treatment for 3 weeks. Cycling ergometry treatment will be performed with Voit AT-200 Black Collection horizontal bike for 20 minutes. Exercise intensity will be adjusted to %40-59 of heart rate reserve (HRR).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complete Decongestive Treatment
Description: While the patients in non-cycling group will get only complete decongestive treatment (CDT) for 3 weeks, the patients in cycling group will get CDT+cycling ergometry treatment for 3 weeks. Cycling ergometry treatment will be performed with Voit AT-200 Black Collection horizontal bike for 20 minutes. Exercise intensity will be adjusted to %40-59 of heart rate reserve (HRR).
Study: NCT05887232

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2 laser
Description: Patient in group A received FCL treatments four sessions with four weeks apart

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2 with Platelet Rich Plasma
Description: Group B received four PRP and FCL sessions 4 weeks apart
Study: NCT04685967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glass ionomer
Description: Equia Forte HT, GC, Tokyo, Japan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bulk-fill composite
Description: SonicFill2, Orange, CA, USA
Study: NCT04515173

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Artificial intelligence diagnosis and treatment assistance system
Description: An artificial intelligence robot that can assist psychiatrists in disease screening, diagnosis, treatment, and follow-up.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Artificial intelligence diagnosis and treatment assistance system
Description: An artificial intelligence robot that can assist psychiatrists in disease screening, diagnosis, treatment, and follow-up.
Study: NCT06200948

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complete Decongestive Treatment
Description: While the patients in non-cycling group will get only complete decongestive treatment (CDT) for 3 weeks, the patients in cycling group will get CDT+cycling ergometry treatment for 3 weeks. Cycling ergometry treatment will be performed with Voit AT-200 Black Collection horizontal bike for 20 minutes. Exercise intensity will be adjusted to %40-59 of heart rate reserve (HRR).
Study: NCT05551117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vobramitamab duocarmazine 2.0 mg (Arm A)
Description: 2.0 mg/kg intravenous (IV) every 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vobramitamab duocarmazine 2.7 mg (Arm B)
Description: 2.7 mg.kg IV every 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vobramitamab duocarmazine
Description: 2.7 mg.kg IV every 4 weeks
Study: NCT05108376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visensia Safety Index (VSI)
Description: Enrolled patients will undergo continuous vital sign monitoring, to be used by the Visensia Safety Index (VSI) to identify early deterioration. If early deterioration is identified, the VSI will produce an alert to notify the RACE team.
Study: NCT03215459

Intervention type: DEVICE
Intervention: Cardiopulmonary Exercise Test
Description: Cardiopulmonary Exercise Test